超重与肥胖患者更早或更强化结直肠癌筛查的成本效果
研究采用经验证的决定分析模型,比较超重与肥胖人群从45岁或40岁开始筛查、或缩短筛查间隔的成本效果。结果显示,从45岁开始每10年一次结肠镜或从40岁开始每年粪便免疫化学检测在所有BMI和性别组中均具成本效果;从40岁开始结肠镜仅对肥胖II-III级男性具成本效果。
要点
- 从45岁开始每10年结肠镜或从40岁开始每年FIT,在所有BMI和性别组中均具成本效果。
- 从40岁开始每10年结肠镜仅对肥胖II-III级男性具成本效果。
- 将结肠镜筛查提前开始始终优于延后开始每5年结肠镜。
核心结论
- 从45岁开始结肠镜筛查或从40岁开始FIT筛查,对正常至III级肥胖的男女均似乎具成本效果。
- 肥胖II-III级男性从40岁开始结肠镜筛查似乎具成本效果。
- 是否将BMI作为单一预测因素或纳入多变量工具来定制结直肠癌筛查尚待决定。
研究设计与样本
- 采用经验证的决定分析模型,比较超重与肥胖人群不同结直肠癌筛查策略的成本效果。
- 策略包括每10年结肠镜(Colo10)、每5年结肠镜(Colo5)或每年粪便免疫化学检测(FIT)。
- 比较筛查起始年龄45岁或40岁而非50岁,或缩短筛查间隔,覆盖正常至III级肥胖的男女。
主要发现
- 无筛查时,超重或肥胖I-III级者的性别特异性结直肠癌总死亡数相似,反映BMI升高时结直肠癌风险增高与预期寿命降低相互抵消。
- 在所有BMI和性别组中,从45岁开始Colo10或从40岁开始FIT在每获得一个质量调整生命年10万美元的阈值下具成本效果。
- 从40岁开始Colo10仅对肥胖II-III级男性具成本效果,每获得一个质量调整生命年分别花费93,300美元和80,400美元。
- 将Colo10提前开始始终优于延后开始Colo5。
- 敏感性分析结果稳健,包括变化全因死亡率、并发症和BMI特异性结直肠癌风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Overweight and obese persons have not only elevated rates of colorectal cancer (CRC), but also higher competing mortality and healthcare spending. We examined the cost-effectiveness of intensified CRC screening in overweight and obese persons. METHODS: We adapted our validated decision analytic model of CRC screening to compare screening starting at 45 or 40 years of age instead of at 50 years of age, or shortening screening intervals, in women and men with body mass index (BMI) ranging from normal to grade III obesity. Strategies included colonoscopy every 10 years (Colo10) or every 5 years (Colo5), or annual fecal immunochemical test. RESULTS: Without screening, sex-specific total CRC deaths were similar for persons with overweight or obesity I-III, reflecting the counterbalancing of higher CRC risk by lower life expectancy as BMI rises. For all BMI and sex groups, Colo10 starting at 45 years of age or FIT starting at 40 years of age were cost-effective at a threshold of $100,000 per quality-adjusted life year gained. Colo10 starting at 40 years of age was cost-effective only for men with obesity II-III, at $93,300 and $80,400 per quality-adjusted life year gained, respectively. Shifting Colo10 to earlier starting ages was always preferred over Colo5 starting at later ages. Results were robust in sensitivity analysis, including varying all-cause mortality, complication, and BMI-specific CRC risks. CONCLUSIONS: CRC screening starting at 45 years of age with colonoscopy, or at 40 years of age with FIT, appears cost-effective for women and men across the range of BMI. In men with obesity II-III, who have the highest CRC but also all-cause mortality risks, colonoscopy starting at 40 years of age appears cost-effective. It remains to be decided whether BMI should be used as a single predictor or incorporated into a multivariable tool to tailor CRC screening.
引用
- Yeoh A, Mannalithara A, Ladabaum U, et al. Cost-Effectiveness of Earlier or More Intensive Colorectal Cancer Screening in Overweight and Obese Patients. Clin Gastroenterol Hepatol. 2022. PMID: 35940514. doi:10.1016/j.cgh.2022.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。